Genmab — Juni 2020

[Solsen]

Just read some of Abbvies history. They are quite offensive in the M&A field. Last year they bought Allergen for $63 bn - yah a good partner we have

[E_L]

Dara SC by JNJ EVP at GS conference from minute 18 https://kvgo.com/GSHC/johnson-johnson-june-2020

[Sukkeralf]

Yes solsen they are very aggressive - the price for pharmacyclics years ago was also very high.

[Sukkeralf]

But they also have shown a more problematic side - when they skipped Galapagos JAK1 inhibitor and went forward with there own JAK1 compound. So quite liked the Q about similar BsAbs in their own pipe being similar to Genmabs

[Sukkeralf]

Now at least they know that we are looking out for that - and Jan also said that he really hoped that was not the case. And Nigel also said NO to that Q

[E_L]

would be fun to know what other companies were in the race for the deal

[kkjoel]

GB, det seneste Bloomberg kursmål jeg har er 1395 fra slut-17. Er de holdt op med at dække eller er jeg bagved kurven?

[Solsen]

I en ny artikel i børsen slås det fast at: "De projekter, der er i discovery-fasen, altså endnu ikke i klinisk udvikling, vil Genmab gennemføre fase 1-forsøg med, og Abbvie har option på at kunne komme med i videreudviklingen af midlerne" - citat slut.

[kkjoel]

Sukker - jeg bemærkede at han svarede meget kort, noget a la "we don't think at that" (kunne godt tolkes: for the time being), istedet for noget mere kategorisk. Måske man kunne lægge noget i det?

[Solsen]

Heri henviser JW også til lignende tidligere aftaler som Janssen og Genentech. Som bekendt endte godt med at forgylde Genentech ejerne

[Solsen]

JW nævner også at de forventer at indsende ansøgning om godkendelse i første indikation for epco i 2022.

[Solsen]

Det er hurtigt !

[E_L]

@Solsen it was written exactly like that in the press release " For the discovery research partnership, Genmab will conduct Phase 1 studies for these programs. AbbVie retains the right to opt-in to program development."

[GeorgeBest]

@kkjoel 11:42 Ikke nogen opdatering på Bloomberg kursmål det senste år, kan ikke gå længere tilbage

[E_L]

Bryan Garnier höjer riktkursen för Genmab till 2 000 danska kronor (1 950), upprepar neutral - BN (Finwire)

[Sukkeralf]

E L - and there is a opt in payment thats not included in the 2 billion milestones

[E_L]

are
you sure it is not included?

[Solsen]

Yes but the question yesterday was - is
these programs in clinical developement alredy. NO

[Sukkeralf]

E L - pretty sure Jan said that. But it could be a small amount

[E_L]

ok